AI주식인사이트AI Stock Insight
C

마크로젠

038290KOSDAQ

47.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

MacroGen, established in 1997, is a precision medicine biotechnology company specializing in genome analysis, offering services such as genome sequencing, oligo synthesis, microarray analysis, and genetically modified mouse production through global genomics centers. Its core business, genome analysis services, accounts for approximately 90% of total revenue, utilizing both CES and NGS technologies to analyze genetic sequences across humans and various organisms. The company enhances its competitive edge by integrating blockchain and AI technologies for data security and expanding into new service areas.

Number of Employees

488people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
59.84Industry Average 15.000.0Point

4.0x industry avg (risky)

PBR
0.70Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-0.12Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
16.09Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲23.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼662.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 11,190Won52-week high 19,52052-week low 10,700
1-month return2.0Point

1m -5.09% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-01